Jagsonpal Pharmaceuticals gained 2.15% after shareholders approved buyback of up to 16 lakh equity shares at ₹250 per share, aggregating ₹40 crore. The proposal was earlier cleared by the Board on March 12, 2026. Management said the buyback aims to optimise capital structure, improve EPS and enhance long-term shareholder value.